Literature DB >> 14657665

Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.

Giovanna Damia1, Massimo Broggini.   

Abstract

The response of cancer cells to treatment with anticancer agents is mediated in part by proteins controlling both the cell cycle progression and the genomic integrity, including p53, p73 and checkpoint proteins chk1 and chk2. We here summarized the cellular functions of these proteins, their alterations in human tumors and the impact of their mutations/alterations on cellular response to treatment, Particular attention has been paid for those studies performed in isogenic cell systems, to minimize as much as possible interference by other alterations invariably present when different cell types are considered. Focus has also be given to the approaches taken to exploit the differential expression of these proteins between normal and tumor cells to improve the selectivity of treatment with anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14657665

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

1.  Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.

Authors:  Salaheldin S Hamed; Robert M Straubinger; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-09       Impact factor: 3.333

2.  Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells.

Authors:  Juni Chakraborty; Shuvomoy Banerjee; Pallab Ray; Dewan Md Sakib Hossain; Sankar Bhattacharyya; Arghya Adhikary; Sreya Chattopadhyay; Tanya Das; Gaurisankar Sa
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

4.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

5.  Phosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradation.

Authors:  Yiping Huang; Edward A Ratovitski
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 6.  P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

Authors:  Xiao-Lan Li; Jianbiao Zhou; Zhi-Rong Chen; Wee-Joo Chng
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

7.  Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma.

Authors:  Samar Omar Rabah
Journal:  Saudi J Biol Sci       Date:  2010-02-24       Impact factor: 4.219

8.  Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.

Authors:  G Chatzinikolaou; D Nikitovic; A Berdiaki; A Zafiropoulos; P Katonis; N K Karamanos; G N Tzanakakis
Journal:  Cell Prolif       Date:  2009-10-21       Impact factor: 6.831

9.  Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.

Authors:  Leander Gaul; Sonja Mandl-Weber; Philipp Baumann; Bertold Emmerich; Ralf Schmidmaier
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

10.  Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.

Authors:  Qingdi Quentin Li; Iawen Hsu; Thomas Sanford; Reema Railkar; Navin Balaji; Carole Sourbier; Cathy Vocke; K C Balaji; Piyush K Agarwal
Journal:  Cell Mol Life Sci       Date:  2017-10-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.